L.R. Silverman

641 total citations
18 papers, 492 citations indexed

About

L.R. Silverman is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, L.R. Silverman has authored 18 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 10 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in L.R. Silverman's work include Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). L.R. Silverman is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). L.R. Silverman collaborates with scholars based in United States, Italy and Australia. L.R. Silverman's co-authors include Shashi Jatiani, Suzanne J. Baker, E. Premkumar Reddy, Pierre Fenaux, Eva Hellström‐Lindberg, Alan F. List, Valeria Santini, C.L. Beach, John M. Bennett and John F. Seymour and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Haematologica.

In The Last Decade

L.R. Silverman

18 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L.R. Silverman United States 9 325 207 160 106 65 18 492
Saskia Gueller United States 14 148 0.5× 199 1.0× 134 0.8× 80 0.8× 67 1.0× 19 468
Toshiya Yokozawa Japan 8 222 0.7× 281 1.4× 107 0.7× 100 0.9× 35 0.5× 17 528
Jamie Wilhelm United States 6 215 0.7× 162 0.8× 85 0.5× 96 0.9× 30 0.5× 13 369
Antonella Russo Rossi Italy 12 151 0.5× 92 0.4× 140 0.9× 93 0.9× 34 0.5× 23 384
Emanuela Messa Italy 11 456 1.4× 277 1.3× 275 1.7× 60 0.6× 15 0.2× 35 629
Florian Perner Germany 10 238 0.7× 293 1.4× 124 0.8× 64 0.6× 16 0.2× 26 471
Ann‐Mari Forsblom Sweden 6 312 1.0× 183 0.9× 170 1.1× 51 0.5× 11 0.2× 12 395
Xiongpeng Zhu China 9 128 0.4× 207 1.0× 66 0.4× 73 0.7× 23 0.4× 24 345
Toshie Ogasawara Japan 8 128 0.4× 114 0.6× 59 0.4× 73 0.7× 23 0.4× 25 280

Countries citing papers authored by L.R. Silverman

Since Specialization
Citations

This map shows the geographic impact of L.R. Silverman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L.R. Silverman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L.R. Silverman more than expected).

Fields of papers citing papers by L.R. Silverman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L.R. Silverman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L.R. Silverman. The network helps show where L.R. Silverman may publish in the future.

Co-authorship network of co-authors of L.R. Silverman

This figure shows the co-authorship network connecting the top 25 collaborators of L.R. Silverman. A scholar is included among the top collaborators of L.R. Silverman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L.R. Silverman. L.R. Silverman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
García-Manero, G., L.R. Silverman, Rami S. Komrokji, et al.. (2015). 57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE. Leukemia Research. 39. S28–S28. 1 indexed citations
2.
Navada, Shyamala, Guillermo Garcia‐Manero, Rosalie Odchimar-Reissig, et al.. (2015). 89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML). Leukemia Research. 39. S45–S45. 1 indexed citations
3.
Fenaux, Pierre, John F. Seymour, Valeria Santini, et al.. (2013). Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. Leukemia Research. 38(2). 258–262. 5 indexed citations
4.
5.
Mesa, Ruben A., Richard T. Silver, Srđan Verstovšek, et al.. (2013). Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 98(9). 1421–1423. 11 indexed citations
6.
Jatiani, Shashi, Suzanne J. Baker, L.R. Silverman, & E. Premkumar Reddy. (2010). JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies. Genes & Cancer. 1(10). 979–993. 173 indexed citations
7.
Rondelli, Damiano, Michael W. Boyer, Tsiporah B. Shore, et al.. (2010). First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol.. Journal of Clinical Oncology. 28(15_suppl). 6535–6535. 3 indexed citations
8.
Fenaux, Pierre, Valeria Santini, John M. Bennett, et al.. (2010). Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS.. Journal of Clinical Oncology. 28(15_suppl). 6503–6503. 10 indexed citations
9.
10.
11.
Silverman, L.R., Pierre Fenaux, Valeria Santini, et al.. (2009). P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Leukemia Research. 33. S133–S134. 1 indexed citations
12.
Santini, Valeria, Pierre Fenaux, G J Mufti, et al.. (2008). Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Journal of Clinical Oncology. 26(15_suppl). 7028–7028. 2 indexed citations
13.
List, Alan F., Pierre Fenaux, G J Mufti, et al.. (2008). Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. Journal of Clinical Oncology. 26(15_suppl). 7006–7006. 39 indexed citations
14.
Mufti, G J, Pierre Fenaux, Eva Hellström‐Lindberg, et al.. (2008). Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS). Journal of Clinical Oncology. 26(15_suppl). 7033–7033. 8 indexed citations
15.
16.
17.
Silverman, L.R. & Kanwar Nasir M. Khan. (1999). "Have You Seen This?" Nonsteroidal Anti-inflammatory Drug-Induced Renal Papillary Necrosis in a Dog. Toxicologic Pathology. 27(2). 244–245. 7 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saskia Gueller Breakdown of academic impact, for papers by Toshiya Yokozawa Breakdown of academic impact, for papers by Jamie Wilhelm Breakdown of academic impact, for papers by Antonella Russo Rossi Breakdown of academic impact, for papers by Emanuela Messa Breakdown of academic impact, for papers by Florian Perner Breakdown of academic impact, for papers by Ann‐Mari Forsblom Breakdown of academic impact, for papers by Xiongpeng Zhu Breakdown of academic impact, for papers by Toshie Ogasawara
Rankless by CCL
2026